APA (7th ed.) Citation

Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., . . . Hochhaus, A. (2021). A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 138(21), 2031-2041. https://doi.org/10.1182/blood.2020009984

Chicago Style (17th ed.) Citation

Réa, Delphine, et al. "A Phase 3, Open-label, Randomized Study of Asciminib, a STAMP Inhibitor, Vs Bosutinib in CML After 2 or More Prior TKIs." Blood 138, no. 21 (2021): 2031-2041. https://doi.org/10.1182/blood.2020009984.

MLA (9th ed.) Citation

Réa, Delphine, et al. "A Phase 3, Open-label, Randomized Study of Asciminib, a STAMP Inhibitor, Vs Bosutinib in CML After 2 or More Prior TKIs." Blood, vol. 138, no. 21, 2021, pp. 2031-2041, https://doi.org/10.1182/blood.2020009984.